Pharmacokinetics, biodistribution, in vitro cytotoxicity and biocompatibility of Vitamin E TPGS coated trans resveratrol liposomes

Colloids and Surfaces B: Biointerfaces

Volumn 145, Issue , 2016, Pages 479-491

  Vijayakumar, Mahalingam Rajamanickam ^a   Vajanthri, Kiran Yellappa ^a   Balavigneswaran, Chelladurai Karthikeyan ^a   Mahto, Sanjeev Kumar ^a   Mishra, Nira ^a   Muthu, Madaswamy S ^a   Singh, Sanjay ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Cancer nanomedicine; Cell uptake of liposomes; Passive brain targeting; PEGylated liposomes; Sustained release; Trans resveratrol

Indexed keywords

BIOCOMPATIBILITY; CELL CULTURE; DISEASES; MEDICAL NANOTECHNOLOGY; PHARMACOKINETICS; RESVERATROL; TUMORS;

BRAIN TARGETING; CELL UPTAKE; PEGYLATED LIPOSOMES; SUSTAINED RELEASE; TRANS-RESVERATROL;

LIPOSOMES;

ALPHA TOCOPHEROL SUCCINATE; MACROGOL; RESVERATROL; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; DRUG CARRIER; LIPOSOME; MACROGOL DERIVATIVE; STILBENE DERIVATIVE; TOCOFERSOLAN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; DRUG TARGETING; GLIOMA; GLIOMA CELL; HEMOLYSIS; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; ZETA POTENTIAL; ANIMAL; BRAIN NEOPLASMS; CHEMISTRY; MALE; NANOMEDICINE; PROCEDURES; RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DRUG CARRIERS; LIPOSOMES; MALE; NANOMEDICINE; POLYETHYLENE GLYCOLS; RATS; STILBENES; VITAMIN E;

EID: 84969793987     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2016.05.037     Document Type: Article

References (54)

1. Rip J., Chen L., Hartman R., van den Heuvel A., Reijerkerk A., van Kregten J., van der Boom B., Appeldoorn C., de Boer M., Maussang D., de Lange E.C., Gaillard P.J. Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood-brain barrier in rats. J. Drug Target. 2014, 22:460-467.
2. Qi N., Cai C., Zhang W., Niu Y., Yang J., Wang L., Tian B., Liu X., Lin X., Zhang Y., Zhang Y., He H., Chen K., Tang X. Sustained delivery of cytarabine-loaded vesicular phospholipid gels for treatment of xenografted glioma. Int. J. Pharm. 2014, 472:48-55.
3. Yang L.-J., Zhou C.-F.U., Lin Z.-X. Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review. Cancer Invest. 2014, 32:31-36.
4. Keunen O., Taxt T., Gruner R., Lund-Johansen M., Tonn J.C., Pavlin T., Bjerkvig R., Niclou S.P., Thorsen F. Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. Adv. Drug Deliv. Rev. 2014, 76:98-115.
5. Miura D., Miura Y., Yagasaki K. Hypolipidemic action of dietary resveratrol a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci. 2003, 73:1393-1400.
6. Muthu M.S., Kulkarni S.A., Raju A., Feng S.S. Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials 2012, 33:3494-3501.
7. Jiang H., Zhang L., Kuo J., Kuo K., Gautam S.C., Groc L., Rodriguez A.I., Koubi D., Jackson Hunter T., Corcoran G.B., Seidman M.D., Levine R.A. Resveratrol-induced apoptotic death in human U251 glioma cells. Mol. Cancer Ther. 2005, 4:554-561.
8. Zhang W., Fei Z., Zhen H.N., Zhang J.N., Zhang X. Resveratrol inhibits cell growth and induces apoptosis of rat C6 glioma cells. J. Neurooncol. 2007, 81:231-240.
9. Sato A., Okada M., Shibuya K., Watanabe E., Seino S., Suzuki K., Narita Y., Shibui S., Kayama T., Kitanaka C. Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells. Stem Cell Res. 2013, 11:601-610.
10. Gagliano N., Aldini G., Colombo G., Rossi R., Colombo R., Gioia M., Milzani A., Dalle-Donne I. The potential of resveratrol against human gliomas. Anticancer Drugs 2010, 21:140-150.
11. Tseng S.H., Lin S.M., Chen J.C., Su Y.H., Huang H.Y., Chen C.K., Lin P.Y., Chen Y. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin. Cancer Res. 2004, 10:2190-2202.
12. Gagliano N., Moscheni C., Torri C., Magnani I., Bertelli A.A., Gioia M. Effect of resveratrol on matrix metalloproteinase-2 (MMP-2) and secreted protein acidic and rich in cysteine (SPARC) on human cultured glioblastoma cells. Biomed. Pharmacother. 2005, 59:359-364.
13. Lin C.-J., Lee C.-C., Shih Y.-L., Lin T.-Y., Wang S.-H., Lin Y.-F., Shih C.-M. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic. Biol. Med. 2012, 52:377-391.
14. Gao Z., Xu M.S., Barnett T.L., Xu C.W. Resveratrol induces cellular senescence with attenuated mono-ubiquitination of histone H2B in glioma cells. Biochem. Biophys. Res. Commun. 2011, 407:271-276.
15. Wang L., Long L., Wang W., Liang Z. Resveratrol, a potential radiation sensitizer for glioma stem cells both in vitro and in vivo. J. Pharmacol. Sci. 2015, 129:216-225.
16. Emília Juan M., Buenafuente J., Casals I., Planas J.M. Plasmatic levels of trans-resveratrol in rats. Food Res. Int. 2002, 35:195-199.
17. Colom H., Alfaras I., Maijo M., Juan M.E., Planas J.M. Population pharmacokinetic modeling of trans-resveratrol and its glucuronide and sulfate conjugates after oral and intravenous administration in rats. Pharm. Res. 2011, 28:1606-1621.
18. Amri A., Chaumeil J.C., Sfar S., Charrueau C. Administration of resveratrol: what formulation solutions to bioavailability limitations?. J. Control. Release 2012, 158:182-193.
19. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32:1377-1382.
20. Lu X., Ji C., Xu H., Li X., Ding H., Ye M., Zhu Z., Ding D., Jiang X., Ding X., Guo X. Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress. Int. J. Pharm. 2009, 375:89-96.
21. Guo W., Li A., Jia Z., Yuan Y., Dai H., Li H. Transferrin modified PEG-PLA-resveratrol conjugates: in vitro and in vivo studies for glioma. Eur. J. Pharmacol. 2013, 718:41-47.
22. Fan Y., Zhang Q. Development of liposomal formulations: from concept to clinical investigations. Asian J. Pharm. Sci. 2013, 8:81-87.
23. Guo L., Fan L., Pang Z., Ren J., Ren Y., Li J., Chen J., Wen Z., Jiang X. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J. Control. Release 2011, 154:93-102.
24. Siegal T., Horowitz A., Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 1995, 83:1029-1037.
25. Cosco D., Paolino D., Maiuolo J., Marzio L.D., Carafa M., Ventura C.A., Fresta M. Ultradeformable liposomes as multidrug carrier of resveratrol and 5-fluorouracil for their topical delivery. Int. J. Pharm. 2015, 489:1-10.
26. Cadena P.G., Pereira M.A., Cordeiro R.B.S., Cavalcanti I.M.F., Barros Neto B., d.Pimentel M.C.C.B., Lima Filho J.L., Silva V.L., Santos-Magalhães N.S. Nanoencapsulation of quercetin and resveratrol into elastic liposomes. Biochim. Biophys. Acta (BBA) - Biomembr. 2013, 1828:309-316.
27. Joraholmen M.W., Skalko-Basnet N., Acharya G., Basnet P. Resveratrol-loaded liposomes for topical treatment of the vaginal inflammation and infections. Eur. J. Pharm. Sci. 2015, 79:112-121.
28. Zhang Z., Tan S., Feng S.-S., Vitamin E. TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012, 33:4889-4906.
29. Collnot E.M., Baldes C., Schaefer U.F., Edgar K.J., Wempe M.F., Lehr C.M., Vitamin E. TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol. Pharm. 2010, 7:642-651.
30. Vijayakumar M.R., Muthu M.S., Singh S. Copolymers of poly(lactic acid) and d-alpha-tocopheryl polyethylene glycol 1000 succinate-based nanomedicines: versatile multifunctional platforms for cancer diagnosis and therapy. Expert Opin. Drug Deliv. 2013, 10:529-543.
31. Muthu M.S., Kulkarni S.A., Xiong J., Feng S.S. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int. J. Pharm. 2011, 421:332-340.
32. Raju A., Muthu M.S., Feng S.S. Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Expert Opin. Drug Deliv. 2013, 10:747-760.
33. Pasut G., Paolino D., Celia C., Mero A., Joseph A.S., Wolfram J., Cosco D., Schiavon O., Shen H., Fresta M. Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy. J. Control. Release 2015, 199:106-113.
34. Singh G., Pai R.S., Pandit V. Development and validation of a HPLC method for the determination of trans-resveratrol in spiked human plasma. J. Adv. Pharm. Technol. Res. 2012, 3:130-135.
35. Siemann E.H., Creasy L.L. Concentration of the phytoalexin resveratrol in wine. Am. J. Enol. Viticult. 1992, 43:49-52.
36. Hung L.M., Su M.J., Chen J.K. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Rad. Biol. Med. 2004, 36:774-781.
37. Singh B., Vuddanda P.R., Kumar R.V.M.V., Saxena P.S., Singh S. Cefuroxime axetil loaded solid lipid nanoparticles for enhanced activity against S. aureus biofilm. Colloids Surf. B Biointerfaces 2014, 121:92-98.
38. Youk H.J., Lee E., Choi M.K., Lee Y.J., Chung J.H., Kim S.H., Lee C.H., Lim S.J. Enhanced anticancer efficacy of alpha-tocopheryl succinate by conjugation with polyethylene glycol. J. Control. Release 2005, 107:43-52.
39. Neophytou C.M., Constantinou C., Papageorgis P., Constantinou A.I. d-Alpha-tocopheryl polyethylene glycol succinate (TPGS) induces cell cycle arrest and apoptosis selectively in survivin-overexpressing breast cancer cells. Biochem. Pharmacol. 2014, 89:31-42.
40. Neophytou C.M., Constantinou A.I. Drug delivery innovations for enhancing the anticancer potential of vitamin E isoforms and their derivatives. BioMed Res. Int. 2015, 2015:16.
41. Constantinou C., Neophytou C.M., Vraka P., Hyatt J.A., Papas K.A., Constantinou A.I. Induction of DNA damage and caspase-independent programmed cell death by vitamin E. Nutr. Cancer 2012, 64:136-152.
42. Bozzuto G., Molinari A. Liposomes as nanomedical devices. Int. J. Nanomed. 2015, 10:975-999.
43. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004, 24:2783-2840.
44. Bai J., Zhou Z., Tang H., Song S., Peng J., Xu Y. Impact of PEGylation on biodistribution and tumor accumulation of Lipid-Mu peptide-DNA. J. Liposome Res. 2013, 23:1-10.
45. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
46. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
47. Marier J.F., Vachon P., Gritsas A., Zhang J., Moreau J.P., Ducharme M.P. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 2002, 302:369-373.
48. Juan M.E., Gonzalez-Pons E., Planas J.M. Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats. J. Nutr. 2010, 140:489-495.
49. Afergan E., Epstein H., Dahan R., Koroukhov N., Rohekar K., Danenberg H.D., Golomb G. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J. Control. Release 2008, 132:84-90.
50. Lv W., Guo J., Li J., Huang L., Ping Q. Distribution of liposomal breviscapine in brain following intravenous injection in rats. Int. J. Pharm. 2005, 306:99-106.
51. Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (London, England) 2011, 6:715-728.
52. Hsu W.-H., Liu S.-Y., Chang Y.-J., Long A.-J., Chang C.-H., Lee T.-W. Strategy for reducing liver uptake of 188Re-liposome by pretreating PEGylated liposomal doxorubicin. J. Nucl. Med. 2012, 53:1206.
53. Atyabi F., Farkhondehfai A., Esmaeili F., Dinarvand R. Preparation of pegylated nano-liposomal formulation containing SN-38: in vitro characterization and in vivo biodistribution in mice. Acta Pharm. (Zagreb, Croatia) 2009, 59:133-144.
54. Chow T.-H., Lin Y.-Y., Hwang J.-J., Wang H.-E., Tseng Y.-L., Wang S.-J., Liu R.-S., Lin W.-J., Yang C.-S., Ting G. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model. Anticancer Res. 2009, 29:2111-2120.